One hundred and twenty patients diagnosed with PHS were assigned into four groups: BV1 (0.01 mg/kg), BV2 (0.005 mg/kg), BV3 (0.0025 mg/kg), and control group (vitamin B1 plus novocain 3% injection) with 15 d of treatment. The outcomes of the study including visual analogue scale (VAS) score and β-endorphin, inflammatory cytokines including interleukin-10 (IL-10), IL-1β and tumor necrosis factor α (TNF-α) and shoulder function score were assessed at baseline, after 10 and 15 d of treatment.
All four groups reported statistically significant improvement in VAS score, motion range, and shoulder function score ( < 0.01), only the BV3 group showed significant increase of anti-inflammatory (IL-10) and decrease of pro-inflammatory (IL-1β, TNF-α) cytokines after treatment ( < 0.05). The BV3 group presented a significant difference between all outcomes compared to the control and other groups.
BV3 groups showed better recovery including reduced pain, improved motor function and normalized inflammatory cytokines than current therapy used in Vietnam and other groups.
方法:将诊断为PHS的120例患者分为四组:BV1(0.01mg/kg),BV2(0.005mg/kg),BV3(0.0025mg/kg),对照组(维生素B1+3%注射用)治疗15d。研究结果包括视觉模拟量表(VAS)评分和β-内啡肽,炎症细胞因子,包括白细胞介素-10(IL-10),基线时评估IL-1β和肿瘤坏死因子α(TNF-α)及肩关节功能评分,治疗后10和15d。
结果:所有四组均报告VAS评分有统计学意义的改善,运动范围,肩关节功能评分(<0.01),只有BV3组显示抗炎(IL-10)显著增加和促炎(IL-1β,TNF-α)细胞因子治疗后(<0.05)。与对照组和其他组相比,BV3组的所有结果之间存在显着差异。
结论:BV3组恢复较好,包括疼痛减轻,与越南和其他组目前使用的治疗方法相比,运动功能得到改善,炎症细胞因子也得到了正常化。